U.S. Marine and Shipping Stock News

The Morning Bull - US Market Morning Update Friday, Mar, 27 2026 US stock futures are mixed this morning, with S&P 500 contracts hovering near flat as investors weigh higher borrowing costs against hotter inflation and geopolitical risk. The US 10 year Treasury yield is holding around 4.41%, which keeps pressure on everything from credit cards to business loans, while the average 30 year mortgage rate sits at 6.38%, keeping home buying more expensive. At the same time, Middle East tensions...

This article examines whether Raymond James Financial at around US$144.20 is offering good value or is priced too high, and walks through what the current price might imply. The stock is up 0.9% over the last 7 days, while the 30 day and year to date returns of a 7.3% decline and an 11.9% decline compare with a 1 year return of 2.4% and a 3 year gain of 63.5% that extends to 82.9% over 5 years. Recent coverage has focused on Raymond James Financial's role within the broader capital markets...

SIGA Technologies (NasdaqGM:SIGA) has declared a special cash dividend for its shareholders. The announcement provides a direct cash return in addition to any regular dividend policy the company may have. The timing of the dividend decision highlights management's current view of the company’s cash position and capital needs. SIGA Technologies focuses on health security solutions, including products designed for infectious disease and biodefense settings. A special cash dividend draws...

We feel now is a pretty good time to analyse Prothena Corporation plc's ( NASDAQ:PRTA ) business as it appears the...

If you are wondering whether Compass Minerals International at around US$23.82 is still priced attractively after its recent run, the key question is how its current share price lines up against its fundamentals. The stock has returned 8.3% over the past week and 19.9% year to date. However, this sits alongside a 2.5% decline over the past month and longer term returns of 150.5% over 1 year, a 26.2% decline over 3 years, and a 60.4% decline over 5 years. Recent coverage has highlighted...

Delta Air Lines (NYSE:DAL) has suspended expedited airport screening and escort services for members of Congress. The pause is tied to the current US government shutdown and cost pressures affecting airline operations. The change is contributing to longer TSA lines and a wider debate about travel privileges for public officials. Delta Air Lines, traded as NYSE:DAL, is a major US carrier focused on passenger and cargo air travel. The decision to suspend special treatment for lawmakers comes...

LCI Industries stock in focus after recent performance shifts LCI Industries (LCII) has drawn investor attention following mixed recent share performance, with a small gain over the past week contrasting with a loss over the past month and flat movement over the past 3 months. See our latest analysis for LCI Industries. Looking beyond the recent swings, the 1 year total shareholder return of 41.45% and 3 year total shareholder return of 31.07% point to momentum that contrasts with the weaker...

Kratos Defense & Security Solutions (NasdaqGS:KTOS) received a new contract from the U.S. Navy's Naval Surface Warfare Center to produce and deliver advanced Oriole solid rocket motors. The award supports missile defense and hypersonic testing programs that use the Oriole system. Kratos also appointed defense industry veteran David King to its Board of Directors. King brings extensive experience growing defense businesses and overseeing large aerospace programs. For investors watching the...

We wouldn't blame Best Buy Co., Inc. ( NYSE:BBY ) shareholders if they were a little worried about the fact that Corie...

Celcuity (NasdaqCM:CELC) received FDA Priority Review for its New Drug Application for gedatolisib in advanced breast cancer. The Priority Review follows strong Phase 3 efficacy results from the VIKTORIA-1 trial in HR-positive, HER2-negative breast cancer. An additional Phase 3 readout for the PIK3CA mutant cohort is upcoming and could further influence treatment standards for this patient group. Celcuity focuses on targeted therapies for cancer, with gedatolisib as a key asset in its...

If you are wondering whether Centene's current share price offers value or just more volatility, it helps to break the story down into what the market has been pricing in and how that compares with fundamentals. The stock closed at US$33.56, with returns of a 5.7% decline over 7 days, a 20.8% decline over 30 days, a 19.7% decline year to date, a 44.3% decline over the last year, a 47.7% decline over 3 years and a 46.9% decline over 5 years. This history sets a very specific backdrop for any...

Krystal Biotech: Stock Performance Context Krystal Biotech (KRYS) has drawn investor attention after a recent pullback, with the stock showing a 1-day return of a 1.39% decline, a 1-month return of a 5.81% decline, and a 1-year return of 37.57%. See our latest analysis for Krystal Biotech. Recent trading has been choppy, with a 30 day share price return of a 5.81% decline contrasting with a 1 year total shareholder return of 37.56%. This indicates that earlier momentum has cooled in the short...

NextDecade Corporation ( NASDAQ:NEXT ) shareholders (or potential shareholders) will be happy to see that insider...

AM Best affirmed the credit ratings and outlook for OneMain Holdings’ insurance subsidiaries, reinforcing its view of their financial strength. The decision reflects AM Best’s current assessment of the subsidiaries’ balance sheet quality, risk management and operating performance. For investors watching OneMain Holdings (NYSE:OMF), this rating affirmation comes alongside a mixed share price record. The stock closed at $53.05, with a 4.0% gain over the past week offsetting a 3.9% decline...

If you are wondering whether Lamb Weston Holdings' current share price reflects its underlying value, this article walks through the key signals you can use to judge that for yourself. The stock most recently closed at US$40.83, with returns of 0.5% over 7 days, a 14.9% decline over 30 days, a 3.5% decline year to date and a 22.1% decline over 1 year, alongside a 57.8% decline over 3 years and a 42.9% decline over 5 years. These moves have kept Lamb Weston on the radar for investors looking...

Comstock Resources announced that its Western Haynesville operations in Texas were selected in March 2026 to host the Texas Natural Gas-Fired Power Generation Hub, a U.S.-Japan joint project to be built and operated by NextEra Energy under Japan’s very large US$550 billion investment commitment. This collaboration positions Comstock near the center of a major new demand source for Western Haynesville gas, potentially reshaping its role in U.S. energy infrastructure. We’ll now examine how...

If you are wondering whether Collegium Pharmaceutical's current share price reflects its real worth, this breakdown will help you see what the numbers are actually saying about value. The stock closed at US$33.42, with returns of 13.1% over 1 year and 37.1% over 3 years, but a 26.0% decline over 30 days and 26.6% decline year to date may have changed how investors think about its risk and reward profile. Recent coverage has focused on Collegium Pharmaceutical in the context of its share...

PureCycle Technologies recently signed a €40 million Innovation Fund grant agreement with the EU’s CINEA to build its ‘ASTRA PP’ polypropylene dissolution recycling facility in Belgium’s Port of Antwerp-Bruges, targeting annual production of 59,000 tonnes of PureFive resin and supporting EU circularity and decarbonization goals. The project is intended to help European customers meet recycled content rules in packaging and end-of-life vehicles, positioning PureCycle as a local supplier of...

Why TG Therapeutics’ new credit facility matters for shareholders TG Therapeutics (TGTX) shares are reacting to a fresh financing move after the company entered a new five year, US$750 million senior secured credit facility with funds managed by Blue Owl Capital. For you as a shareholder or potential investor, the key points are the repayment of the prior US$250 million facility, a net US$500 million in non dilutive capital, and access to as much as US$1 billion in total debt capacity at the...

Golar LNG (NasdaqGS:GLNG) has launched a formal review of options for the business, including a possible sale, merger, asset divestitures, or changes to its corporate structure. The company has appointed Goldman Sachs as financial advisor to support this process. The review aims to assess ways to accelerate growth initiatives and evaluate how the current structure supports long term objectives. For investors watching Golar LNG at a share price of $54.06, the timing of this review follows a...

Paycom Software (NYSE:PAYC) has been named best software in multiple categories in G2’s Spring 2026 Grid Reports, based on customer reviews. The company was also recognized as a 2026 Platinum Employer on the inaugural Where You Work Matters List. Paycom is reportedly the only firm in its sector to receive the Platinum Employer distinction. Paycom focuses on HR and payroll software, so third party recognition of product quality and customer satisfaction can matter for buyers comparing...

Wondering if ONE Gas at around US$85.79 is priced for opportunity or already fully valued? This article walks through the key signals that matter for you. The stock has delivered a 10.8% return year to date and 20.4% over the last year, which sits against a modest 0.5% move over the past month and a 0.4% decline over the last week. Recent coverage has focused on ONE Gas as a regulated gas utility, highlighting its role in providing essential services and the way investors often look to such...

Investors may be wondering whether Protagonist Therapeutics at around US$102 still offers value, or if most of the opportunity is already priced in. The stock has posted returns of 0.5% over the last 7 days, 16.9% over the last 30 days, 17.2% year to date and 106.7% over the last year. This naturally raises questions about how much of the story is already reflected in the share price. Recent news flow around Protagonist Therapeutics has focused on its progress as a biotech name and how the...

A. O. Smith (AOS) is back on investors’ radar after recent trading left the shares with mixed short term performance, including a 1 day decline and a gain over the past week. See our latest analysis for A. O. Smith. The recent 1 day share price decline of 1.93% and 30 day share price return of negative 15.01% sit against a more muted 1 year total shareholder return of 0.08%. This suggests that shorter term momentum has faded even as longer term outcomes have been relatively flat. If you are...